Knockdown of RFC3 enhances the sensitivity of colon cancer cells to oxaliplatin by inducing ferroptosis
Fundamental & Clinical Pharmacology · 2025-02 · 39 (1)
DOI: 10.1111/fcp.13044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, online erschienen am 03.01.2025. Verfasst von Youyi Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department Oncology Radiotherapy, The Third Affiliated Hospital of Wenzhou Medical University, Rui'an People Hospital, Zhejiang, China. Hauptthemen laut MEDLINE: Oxaliplatin, Ferroptosis, Drug Resistance, Neoplasm, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Background
The development of resistance to oxaliplatin is a multifaceted process, often involving modifications in drug transport, DNA repair mechanisms, and the ability of cells to evade drug‐induced apoptosis.
Objective
To evaluate whether knocking down RFC3 promotes the sensitivity of colorectal cancer (CRC) cells to oxaliplatin, potentially offering a new approach to combat drug resistance. Methods siRNA‐mediated knockdown of RFC3 was employed in colorectal cancer cell lines to assess the impact on oxaliplatin responsiveness. Cell viability assays, clonogenic survival assays, and flow cytometry were conducted to evaluate the effects on cell growth and apoptosis. Additionally, immunoblot analysis was used to scrutinize modifications in the expression of pivotal protein expression in the Wnt/β‐catenin/GPX4 axis.
Results
RFC3 is highly expressed in CRC tissues and associated with prognosis. Knocking down RFC3 enhances the sensitivity of CRC cells to oxaliplatin. Additionally, the reduction of RFC3 promotes the susceptibility of chemoresistant tumor cells to oxaliplatin by inducing ferroptosis. Furthermore, the knockdown of RFC3 disrupts the Wnt/β‐catenin/GPX4 axis.
Conclusion
Depletion of RFC3 enhances the sensitivity of CRC cells to oxaliplatin via inducing ferroptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department Oncology Radiotherapy, The Third Affiliated Hospital of Wenzhou Medical University, Rui'an People Hospital, Zhejiang, China.
ORCID-Profile: Fuyao Li
Zitieren
APA
Wu, Y., Chen, T., Wu, S., Huang, Y., & Li, F. (2025). Knockdown of RFC3 enhances the sensitivity of colon cancer cells to oxaliplatin by inducing ferroptosis. Fundamental & Clinical Pharmacology, 39(1). https://doi.org/10.1111/fcp.13044
Vancouver
Wu Y, Chen T, Wu S, Huang Y, Li F. Knockdown of RFC3 enhances the sensitivity of colon cancer cells to oxaliplatin by inducing ferroptosis. Fundamental & Clinical Pharmacology. 2025;39(1). doi:10.1111/fcp.13044
BibTeX
@article{Wu2025,
author = {Wu, Youyi and Chen, Tingting and Wu, Songsong and Huang, Yiwei and Li, Fuyao},
title = {Knockdown of RFC3 enhances the sensitivity of colon cancer cells to oxaliplatin by inducing ferroptosis},
journal = {Fundamental & Clinical Pharmacology},
year = {2025},
volume = {39},
number = {1},
doi = {10.1111/fcp.13044}
}
EUVIMED